Roche Partners with Blueprint Medicine on Cancer Immunotherapy

 

Blueprint Medicines said today it is launching a $1 billion-plus collaboration with Roche to discover, develop, and commercialize up to five small-molecule therapeutics targeting kinases deemed important in cancer immunotherapy.

The five candidates could be either single products or products to be combined with Roche therapeutics.

Roche will hold options triggered upon achievement of Phase I proof-of-concept for an exclusive license to each drug candidate developed under the collaboration.

Subscribe to get the latest news